Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED)

• Sponsor: Organon and Co (Industry)
• Overall Status: Completed
• CT.gov ID: NCT00381485
• Collaborator: Novartis (Industry)
• Enrollment: 834
• Arms: 3
• Actual Duration (Months): 18

Study Details

Study Description

Brief Summary

This is a randomized, multicenter, double blind, parallel-group study evaluating the efficacy of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 400/10 mcg twice daily (BID) compared with MF MDI 400 mcg BID for 12 weeks. Prior to the 12-week double-blind treatment period, subjects will receive open-label MF MDI 400 mcg BID for 2 to 3 weeks during the run-in period. Efficacy will be measured by the area under the curve from 0 to 12 hours [AUC](0-12 hr) of the change from Baseline to the Week 12 Endpoint in forced expiratory volume in one second (FEV1).

Condition or Disease	Intervention/Treatment	Phase
Asthma	Drug: Mometasone furoate/formoterol (MF/F) combination; Drug: Mometasone furoate/formoterol (MF/F) combination; Drug: Mometasone furoate MDI (MF MDI)	Phase 3

Study Design

• Study Type: Interventional
• Actual Enrollment: 834 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: A 12-Week Efficacy and Safety Study of Two Doses of Mometasone Furoate/Formoterol Combination Formulation Compared With Mometasone Furoate Monotherapy, in Persistent Asthmatics Previously Treated With High-Dose Inhaled Glucocorticosteroids
• Actual Study Start Date: Jul 1, 2006
• Actual Primary Completion Date: Jan 1, 2008
• Actual Study Completion Date: Jan 1, 2008

Arms and Interventions

Arm	Intervention/Treatment
Experimental: MF/F MDI 400/10 mcg BID Mometasone Furoate 400 mcg and formoterol 10 mcg fixed dose combination taken twice daily Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period	Drug: Mometasone furoate/formoterol (MF/F) combination; MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks; Other Names: SCH 418131
Experimental: MF/F MDI 200/10 mcg BID Mometasone Furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period	Drug: Mometasone furoate/formoterol (MF/F) combination; MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks; Other Names: SCH 418131
Active Comparator: MF MDI 400 mcg BID Mometasone Furoate 400 mcg taken twice daily Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period	Drug: Mometasone furoate MDI (MF MDI); MF 400 mcg via metered dose inhaler twice daily for 12 weeks; Other Names: SCH 32088

Outcome Measures

Primary Outcome Measures

1. Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) [Baseline to Week 12]

   The average of the two predose FEV1 measurements (30 minutes prior to dosing and 0 hour, immediately prior to dosing) at the Baseline Visit were subtracted from each of the serial measurements over the 12-hour period. The AUC was calculated based on these changes from Baseline evaluations. The comparison was for MF/F versus MF. Standard deviation was pooled.

Secondary Outcome Measures

1. Change From Baseline to Week 12 in Asthma Control Questionnaire (ACQ) Total Score [Baseline to Week 12]

   ACQ consists of seven questions each scaled from 0 (best case) to 6 (worst case). The ACQ Total score was the mean of the individual seven questions. The comparison was for MF/F versus placebo. Standard deviation was pooled.

2. Change From Baseline to Week 12 in Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ[S]) Total Score [Baseline to Week 12]

   AQLQ(S) consists of 32 questions each scaled from 1 (worst case) to 7 (best case). The AQLQ(S) Total score was the mean of the individual 32 questions. The comparison was for MF/F versus placebo. Standard deviation was pooled.

3. Change From Baseline in Proportion of Nights Across the Treatment Period With Nocturnal Awakenings Due to Asthma That Require Use of Short-Acting Beta Agonists (SABA) [12-week Treatment Period]

   Baseline was the proportion of nights of the last week (Days -7 to 1) prior to first dose with nocturnal awakenings. Scale is measured as 0 to 1 with 0 = no awakenings to 1 = awakenings every night. The comparison was for MF/F versus placebo. Standard deviation was pooled.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 12 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• A subject must be at least 12 years of age, of either sex, and of any race, with a diagnosis of asthma of at least 12 months duration that is consistent with the following definition:

• The diagnosis of asthma is based upon clinical history and examination, pulmonary function parameters, and response to beta2-agonists, according to international guidelines.

• A subject must have been using a high dose of inhaled glucocorticosteroid (ICS) either alone or in combination with a long-acting beta2 agonist (LABA) for at least 12 weeks prior to Screening, with no use of oral glucocorticosteroids within 30 days prior to Screening. A subject must have been on a stable asthma regimen (daily dose unchanged) for at least 2 weeks prior to Screening. High daily doses of ICS are defined as follows:

• 1000 mcg beclomethasone chlorofluorocarbon (CFC)

• 500 mcg beclomethasone hydrofluoroalkane (HFA)

• 1000 mcg budesonide dry powder inhaler (DPI)

• 2000 mcg flunisolide

• 500 mcg fluticasone

• 400 mcg MF

• 2000 mcg triamcinolone acetonide

• 320 mcg ciclesonide

Note: Dose delivery by method or modality other than those noted above must be equivalent.

• A subject must have experienced at least one severe exacerbation requiring a course of oral glucocorticosteroid 2 to 12 months prior to Screening.

• If, based upon the medical judgment of the investigator, there is no inherent harm in changing the subject's current asthma therapy, then the subject (and parent/guardian, if applicable) must be willing to discontinue his/her prescribed ICS or ICS/LABA prior to initiating MF MDI run-in medication.

• To document the diagnosis of asthma and assure the subject's responsiveness to bronchodilators before randomization, one of the following methods can be used at the

Screening Visit, Day-14, or thereafter, but prior to the Baseline Visit:

• The subject must demonstrate an increase in absolute FEV1 of at least 12% and at least 200 mL within approximately 15 to 20 minutes after administration of four inhalations of albuterol/salbutamol (total dose of 360 to 400 mcg).

• The subject must demonstrate a peak expiratory flow (PEF) variability of more than 20% expressed as a percent of the best and lowest morning pre-bronchodilator PEF over at least 1 week.

• The subject must demonstrate a diurnal variation in PEF of more than 20% based on the difference between the prebronchodilator (before taking albuterol/salbutamol) morning value and the postbronchodilator value (after taking albuterol/salbutamol) from the evening before, expressed as a percentage of the mean daily PEF value. Note: If a subject is to qualify using diurnal variation, the subject should be instructed to perform his/her PEF evaluation after using his/her bronchodilator in the evening.

• At the Screening Visit, the subject's FEV1 must be >=50% predicted when all restricted medications have been withheld for the appropriate intervals.

• At the Baseline Visit, the subject's FEV1 must be >=50% and <=85% predicted when all restricted medications have been withheld for the appropriate intervals.

• The subject (and parent/guardian for a subject under the age of legal consent) must be willing to give written informed consent and be able to adhere to dose and visit schedules.

• A female subject of childbearing potential must be using a medically acceptable, adequate form of birth control. This includes:

• hormonal contraceptive as prescribed by a physician (oral combined, hormonal vaginal ring, hormonal implant or depot-injectable);

• medically prescribed intra-uterine device (IUD);

• medically prescribed topically-applied transdermal contraceptive patch;

• condom in combination with a spermicide (double-barrier method);

• monogamous relationship with a male partner who has had a vasectomy. The subject must have started this birth control method at least 3 months prior to Screening (with the exception of condom in combination with spermicide), and must agree to continue its use for the duration of the study. A female subject of childbearing potential who is not currently sexually active must agree and consent to using a medically acceptable method should she become sexually active during the course of this study. Women who have been surgically sterilized or are at least 1 year postmenopausal are not considered to be of childbearing potential. A female subject of childbearing potential must have a negative serum pregnancy test at Screening in order to be considered eligible for the open-label MF MDI Run-in Period.

Exclusion Criteria:

• A subject who demonstrates a change (increase or decrease) in absolute FEV1 of >20% at any time from the Screening Visit up to and including the Baseline Visit. Pulmonary function tests (PFTs) will be performed in the morning.

• A subject who requires the use of >8 inhalations per day of short-acting beta agonists (SABA) MDI or >=2 nebulized treatments per day of 2.5 mg SABA, on any 2 consecutive days from the Screening Visit up to and including the Baseline Visit.

• A subject who experiences a decrease in AM or PM peak expiratory flow (PEF) below the Run-in Period stability limit on any 2 consecutive days prior to randomization.

• A subject who experiences a clinical asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization due to asthma, or treatment with additional, excluded asthma medication [including oral or other systemic corticosteroids, but allowing SABAs]), at any time from the Screening Visit up to and including the Baseline Visit.

• A subject who has been treated in the emergency room (for a severe asthma exacerbation), or admitted to the hospital for management of airway obstruction, within the last 3 months.

• A subject who has ever required ventilator support for respiratory failure secondary to asthma.

• A subject who has experienced an upper or lower respiratory tract infection (viral or bacterial) within the previous 2 weeks prior to Screening and Baseline Visits. Visits can be rescheduled 2 weeks after complete resolution of the event to re-assess eligibility.

• A subject who is a smoker or ex-smoker and has smoked within the previous year or has had a cumulative smoking history >10 pack-years.

• A subject with a clinically significant abnormal vital sign.

• A subject with evidence (upon visual inspection, laboratory culture is not required) of clinically significant oropharyngeal candidiasis at Baseline (Visit 3) with or without treatment. If there is evidence of oropharyngeal candidiasis at Screening or Pre-Baseline Visit, the subject may be treated as appropriate and the Baseline Visit can be scheduled upon resolution. If there is evidence of oropharyngeal candidiasis at the Baseline Visit, the subject may be treated as appropriate and the visit can be rescheduled upon resolution.

• A subject with a history of clinically significant renal, hepatic, cardiovascular, metabolic, neurologic, hematologic, ophthalmologic, respiratory, gastrointestinal, cerebrovascular, or other significant medical illness or disorder which, in the judgment of the investigator, could interfere with the study, or require treatment that might interfere with the study. Specific examples include (but are not limited to) insulin-dependent diabetes, hypertension being treated with beta blockers, active hepatitis, coronary artery disease, arrhythmia, stroke, severe rheumatoid arthritis, chronic open-angle glaucoma or posterior subcapsular cataracts, acquired immune deficiency syndrome (AIDS), or conditions that may interfere with respiratory function such as clinically diagnosed chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis, cystic fibrosis, etc. Other conditions that are well-controlled and stable (eg, hypertension not requiring beta blockers) will not prohibit participation if deemed appropriate per the investigator's judgment.

• A subject who is known to be allergic to or intolerant of ICS, beta2 agonists, or any of the excipients present in the medications used in this study.

• A female subject who is breast-feeding, pregnant, or intends to become pregnant while participating in this study.

• A subject who is a known illicit drug user.

• A subject who is known to be human immunodeficiency virus (HIV) positive (HIV testing will not be conducted in this study).

• A subject who is unable to correctly use an oral MDI inhaler.

• A subject who has been taking any of the restricted medications prior to Screening without meeting the required washout timeframes.

• A subject who cannot adhere to the permitted concomitant medications and prohibited medications.

• A subject participating in this study may not participate in this same study at another investigational site. In addition, a subject cannot participate in a different investigational study at any site, during the same timeframe of this study.

• A subject must not be randomized into this study more than once.

• No person directly associated with the administration of the study may participate as a study subject. No family member of the investigational study staff may participate in this study.

• A subject who previously participated in a trial with MF/F.

• Subjects with a history of significant QTC prolongation (ie, QTc>500 msec) are excluded from participation in the study.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Organon and Co
• Novartis

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Organon and Co
• ClinicalTrials.gov Identifier: NCT00381485
• Other Study ID Numbers: P04431; Doc ID: 3166301; EUDRACT No.: 2005-005910-20
• First Posted: Sep 27, 2006
• Last Update Posted: Feb 15, 2022
• Last Verified: Feb 1, 2022

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Additional relevant MeSH terms: Asthma; Mometasone Furoate; Formoterol Fumarate

Study Results

Participant Flow

Pre-assignment Detail	834 participants enrolled in the open-label Run-In Period, of which 728 participants were randomized into 1 of 3 arms. Of 728 randomized participants, 643 participants overall completed the Treatment Period, while 85 participants overall discontinued investigational treatment early. All randomized participants received ≥1 dose of study medication.

Arm/Group Title	Open-Label MF MDI 400 mcg BID	MF/F MDI 400/10 mcg BID	MF/F MDI 200/10 mcg BID	MF MDI 400 mcg BID
Arm/Group Description	Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period.	Participants received mometasone Furoate 400 mcg and formoterol 10 mcg fixed dose combination taken twice daily for 12 weeks.	Participants received mometasone Furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily for 12 weeks.	Participants received Mometasone Furoate 400 mcg taken twice daily for 12 weeks.
Period Title: Open-Label Run-In Period
STARTED	834	0	0	0
COMPLETED	728	0	0	0
NOT COMPLETED	106	0	0	0
Period Title: Open-Label Run-In Period
STARTED	0	255	233	240
COMPLETED	0	228	208	207
NOT COMPLETED	0	27	25	33

Baseline Characteristics

Arm/Group Title	MF/F MDI 400/10 mcg BID	MF/F MDI 200/10 mcg BID	MF MDI 400 mcg BID	Total
Arm/Group Description	Participants received mometasone Furoate 400 mcg and formoterol 10 mcg fixed dose combination taken twice daily for 12 weeks.	Participants received mometasone Furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily for 12 weeks.	Participants received Mometasone Furoate 400 mcg taken twice daily for 12 weeks.	Total of all reporting groups
Overall Participants	255	233	240	728
Age (Count of Participants)
<=18 years	23 9%	18 7.7%	22 9.2%	63 8.7%
Between 18 and 65 years	200 78.4%	189 81.1%	189 78.8%	578 79.4%
>=65 years	32 12.5%	26 11.2%	29 12.1%	87 12%
Sex: Female, Male (Count of Participants)
Female	138 54.1%	135 57.9%	136 56.7%	409 56.2%
Male	117 45.9%	98 42.1%	104 43.3%	319 43.8%

Outcome Measures

1. Primary Outcome

Title	Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)
Description	The average of the two predose FEV1 measurements (30 minutes prior to dosing and 0 hour, immediately prior to dosing) at the Baseline Visit were subtracted from each of the serial measurements over the 12-hour period. The AUC was calculated based on these changes from Baseline evaluations. The comparison was for MF/F versus MF. Standard deviation was pooled.
Time Frame	Baseline to Week 12

Outcome Measure Data

Analysis Population Description

Efficacy analyses were based on randomized subjects with Baseline and any post-baseline data (intent-to-treat principle).

Arm/Group Title	MF/F MDI 400/10 mcg BID	MF/F MDI 200/10 mcg BID	MF MDI 400 mcg BID
Arm/Group Description	Participants received mometasone Furoate 400 mcg and formoterol 10 mcg fixed dose combination taken twice daily for 12 weeks.	Participants received mometasone Furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily for 12 weeks.	Participants received Mometasone Furoate 400 mcg taken twice daily for 12 weeks.
Measure Participants	231	204	211
Least Squares Mean (Standard Deviation) [Liter x hour]	4.19 (3.63)	3.59 (3.63)	2.04 (3.63)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	MF/F MDI 400/10 mcg BID, MF MDI 400 mcg BID
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	ANCOVA
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	MF/F MDI 200/10 mcg BID, MF MDI 400 mcg BID
	Comments
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	ANCOVA
	Comments

2. Secondary Outcome

Title	Change From Baseline to Week 12 in Asthma Control Questionnaire (ACQ) Total Score
Description	ACQ consists of seven questions each scaled from 0 (best case) to 6 (worst case). The ACQ Total score was the mean of the individual seven questions. The comparison was for MF/F versus placebo. Standard deviation was pooled.
Time Frame	Baseline to Week 12

Outcome Measure Data

Analysis Population Description

Efficacy analyses were based on randomized subjects with Baseline and any post-baseline data (intent-to-treat principle).

Arm/Group Title	MF/F MDI 400/10 mcg BID	MF/F MDI 200/10 mcg BID	MF MDI 400 mcg BID
Arm/Group Description	Participants received mometasone Furoate 400 mcg and formoterol 10 mcg fixed dose combination taken twice daily for 12 weeks.	Participants received mometasone Furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily for 12 weeks.	Participants received Mometasone Furoate 400 mcg taken twice daily for 12 weeks.
Measure Participants	222	205	206
Least Squares Mean (Standard Deviation) [Units on a Scale]	-0.58 (0.63)	-0.59 (0.63)	-0.42 (0.63)

3. Secondary Outcome

Title	Change From Baseline to Week 12 in Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ[S]) Total Score
Description	AQLQ(S) consists of 32 questions each scaled from 1 (worst case) to 7 (best case). The AQLQ(S) Total score was the mean of the individual 32 questions. The comparison was for MF/F versus placebo. Standard deviation was pooled.
Time Frame	Baseline to Week 12

Outcome Measure Data

Analysis Population Description

Efficacy analyses were based on randomized subjects with Baseline and any post-baseline data (intent-to-treat principle).

Arm/Group Title	MF/F MDI 400/10 mcg BID	MF/F MDI 200/10 mcg BID	MF MDI 400 mcg BID
Arm/Group Description	Participants received mometasone Furoate 400 mcg and formoterol 10 mcg fixed dose combination taken twice daily for 12 weeks.	Participants received mometasone Furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily for 12 weeks.	Participants received Mometasone Furoate 400 mcg taken twice daily for 12 weeks.
Measure Participants	223	205	208
Least Squares Mean (Standard Deviation) [Units on a Scale]	0.51 (0.70)	0.61 (0.70)	0.50 (0.70)

4. Secondary Outcome

Title	Change From Baseline in Proportion of Nights Across the Treatment Period With Nocturnal Awakenings Due to Asthma That Require Use of Short-Acting Beta Agonists (SABA)
Description	Baseline was the proportion of nights of the last week (Days -7 to 1) prior to first dose with nocturnal awakenings. Scale is measured as 0 to 1 with 0 = no awakenings to 1 = awakenings every night. The comparison was for MF/F versus placebo. Standard deviation was pooled.
Time Frame	12-week Treatment Period

Outcome Measure Data

Analysis Population Description

Efficacy analyses were based on randomized subjects with Baseline and any post-baseline data (intent-to-treat principle).

Arm/Group Title	MF/F MDI 400/10 mcg BID	MF/F MDI 200/10 mcg BID	MF MDI 400 mcg BID
Arm/Group Description	Participants received mometasone Furoate 400 mcg and formoterol 10 mcg fixed dose combination taken twice daily for 12 weeks.	Participants received mometasone Furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily for 12 weeks.	Participants received Mometasone Furoate 400 mcg taken twice daily for 12 weeks.
Measure Participants	255	233	239
Least Squares Mean (Standard Deviation) [Proportion of nights]	-0.10 (0.17)	-0.10 (0.17)	-0.05 (0.17)

Adverse Events

Time Frame	Open-Label Run-In + DB Treatment Period (Day -21 to Week 12)
Adverse Event Reporting Description	834 participants enrolled in the OL Run-In Period, of which 728 participants completed and were randomized into 3 arms and treated in the DB treatment period. AEs were reported separately for the OL Run-In Period arm and the Treatment Period arms.
Arm/Group Title	MF/F MDI 400/10 mcg BID		MF/F MDI 200/10 mcg BID		MF MDI 400 mcg BID		Open-Label MF MDI 400 mcg BID
Arm/Group Description	Participants received mometasone Furoate 400 mcg and formoterol 10 mcg fixed dose combination taken twice daily for 12 weeks.		Participants received mometasone Furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily for 12 weeks.		Participants received Mometasone Furoate 400 mcg taken twice daily for 12 weeks.		Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period.
All Cause Mortality
	MF/F MDI 400/10 mcg BID		MF/F MDI 200/10 mcg BID		MF MDI 400 mcg BID		Open-Label MF MDI 400 mcg BID
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)		/ (NaN)		/ (NaN)
Serious Adverse Events
	MF/F MDI 400/10 mcg BID		MF/F MDI 200/10 mcg BID		MF MDI 400 mcg BID		Open-Label MF MDI 400 mcg BID
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	2/255 (0.8%)		3/233 (1.3%)		3/240 (1.3%)		2/834 (0.2%)
Gastrointestinal disorders
Abdominal Pain	0/255 (0%)	0	1/233 (0.4%)	1	0/240 (0%)	0	0/834 (0%)	0
Colitis Ulcerative	0/255 (0%)	0	0/233 (0%)	0	1/240 (0.4%)	1	0/834 (0%)	0
Colonic Polyp	0/255 (0%)	0	0/233 (0%)	0	1/240 (0.4%)	1	0/834 (0%)	0
Diarrhoea	0/255 (0%)	0	0/233 (0%)	0	0/240 (0%)	0	1/834 (0.1%)	1
General disorders
Chest Pain	0/255 (0%)	0	0/233 (0%)	0	1/240 (0.4%)	1	0/834 (0%)	0
Injury, poisoning and procedural complications
Drug Exposure During Pregnancy	0/255 (0%)	0	1/233 (0.4%)	1	0/240 (0%)	0	0/834 (0%)	0
Investigations
Alanine Aminotransferase Increased	0/255 (0%)	0	0/233 (0%)	0	0/240 (0%)	0	1/834 (0.1%)	1
Aspartate Aminotransferase Increased	0/255 (0%)	0	0/233 (0%)	0	0/240 (0%)	0	1/834 (0.1%)	1
Metabolism and nutrition disorders
Dehydration	0/255 (0%)	0	0/233 (0%)	0	0/240 (0%)	0	1/834 (0.1%)	1
Pregnancy, puerperium and perinatal conditions
Abortion Spontaneous	0/255 (0%)	0	1/233 (0.4%)	1	0/240 (0%)	0	0/834 (0%)	0
Psychiatric disorders
Suicide Attempt	0/255 (0%)	0	1/233 (0.4%)	2	0/240 (0%)	0	0/834 (0%)	0
Renal and urinary disorders
Renal Artery Stenosis	1/255 (0.4%)	1	0/233 (0%)	0	0/240 (0%)	0	0/834 (0%)	0
Respiratory, thoracic and mediastinal disorders
Asthma	1/255 (0.4%)	1	0/233 (0%)	0	0/240 (0%)	0	0/834 (0%)	0
Haemoptysis	0/255 (0%)	0	0/233 (0%)	0	1/240 (0.4%)	1	0/834 (0%)	0
Other (Not Including Serious) Adverse Events
	MF/F MDI 400/10 mcg BID		MF/F MDI 200/10 mcg BID		MF MDI 400 mcg BID		Open-Label MF MDI 400 mcg BID
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	12/255 (4.7%)		8/233 (3.4%)		13/240 (5.4%)		6/834 (0.7%)
Infections and infestations
Nasopharyngitis	12/255 (4.7%)	13	8/233 (3.4%)	8	13/240 (5.4%)	14	6/834 (0.7%)	6

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.